# Snelheid van lipidedoelbereik en langetermijnuitkomsten na acuut coronair syndroom

*geplaatst 2026-02-14 · Cholesterol · Terapevticheskii arkhiv · doi 10.26442/00403660.2025.12.203499 · https://hartvaat.nl/2026/02/14/snelheid-van-lipidedoelbereik-en-langetermijnuitkomsten-na-acuut-coronair-syndro/*

Bij patiënten met een acuut coronair syndroom werd onderzocht hoe snel lipidedoelen bereikt werden met meervoudige lipidenverlagende therapie, waaronder de PCSK9-remmer alirocumab. Het tijdstip van therapiestart bleek van invloed op het risico op ongunstige uitkomsten gedurende 18 maanden follow-up.

## English: [Time to achieve target lipid metabolism parameters and its impact on long-term outcomes after acute coronary syndrome in conditions of multicomponent lipid-lowering therapy].

A Russian study evaluated the effect of early versus delayed initiation of alirocumab on the time to achieve lipid targets and 18-month outcomes after acute coronary syndrome, demonstrating the importance of early treatment initiation.

## Abstract (original, from the publication)

AIM: To evaluate the effect of the initiation time of lipid-lowering therapy (LLT) with the use of the proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor alirocumab on the incidence of adverse outcomes during 18-month follow-up after acute coronary syndrome (ACS). MATERIALS AND METHODS: Two groups of patients were observed. In both groups iPCSK9 alirocumab was prescribed within a year after ACS as part of multicomponent LLT: Group 1 (n=20) - alirocumab therapy was started 3 or more months after ACS, Group 2 (n=18) - alirocumab was started up to 3 months after ACS. Control visits were performed at 3, 6, 12 and 18 months after ACS to assess the character of LLT, long-term outcomes and dynamics of low-density lipoprotein cholesterol. RESULTS: In groups 1 and 2, the proportions of those who achieved the target low-density lipoprotein cholesterol after 6 and 12 months, respectively, were 40.0 and 83.3% (p=0.008), 55.0 and 88.9% (p=0.024). A more than three-fold decrease in the need for rehospitalizations for any and cardiovascular reasons was noted among patients with an earlier start of PCSK9-targeted therapy. The need for cardiovascular hospitalizations directly correlated with the period (number of months) before alirocumab was prescribed (R=0.44; p=0.006). CONCLUSION: The use of alirocumab as a part of outpatient low-density lipoprotein cholesterol LLT provides a powerful corrective effect on the lipid profile, as well as an improvement in long-term outcomes after ACS. The positive results of this therapy are especially noticeable when it is started within 3 months after the cardiovascular event.

Auteurs: A A Nekrasov, E S Timoshchenko, S G Erofeeva, T A Nekrasova, F N Muradova, E S Kuzyakina

---
Bron: Terapevticheskii arkhiv, https://doi.org/10.26442/00403660.2025.12.203499. Bijgewerkt 2026-07-03T13:24:38Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.